BioSpace News Archive

Achilles Therapeutics plc (NASDAQ: ACHL), today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, which is being held in a virtual format from June 4-8, 2021.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that Dr. Jaume Mora, M.D., Ph.D. from SJD Barcelona Children’s Hospital will present frontline data for DANYELZA

Y-mAbs Therapeutics, Inc. announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma at the American Society of Clinical Oncology Virtual Annual Meeting on June 4, 2021.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) following two Phase 2 clinical trials

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant

Auransa, Inc., an artificial intelligence (AI) company developing precision medicines in areas of unmet medical needs, and Polaris Quantum Biotech (POLARISqb), a quantum drug design company, announced a research collaboration addressing therapeutics for neglected diseases disproportionately affecting women.

Eli Lilly and Company (NYSE: LLY) today announced new data for the investigational use of Verzenio® (abemaciclib) in high risk early breast cancer, and for its oral selective estrogen receptor degrader (SERD) LY3484356 at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Amgen (NASDAQ:AMGN) today announced updated results for investigational bemarituzumab in combination with chemotherapy from the Phase 2 FIGHT trial.

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.